Kiniksa CFO granted 31K-share option, 7.8K RSUs
Kiniksa’s CFO received new RSU and option grants while earlier RSUs vested and converted into Class A Ordinary Shares, with some shares withheld to cover costs.
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals International, plc (KNSA) reported insider equity activity by its chief financial officer, Mark Ragosa, on September 1, 2026. He received a grant of 7,800 Restricted Share Units and a share option for 31,150 Class A Ordinary Shares at an exercise price of $79.28 per share, with long-term vesting schedules. On the same date, several earlier RSU grants vested and were converted into Class A Ordinary Shares, and 4,404 shares were delivered or withheld for payment of exercise price or tax liability. No Rule 10b5‑1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
9,104 shares exercised/converted
Exercise
11 txns
Insider
Ragosa Mark
Role
CHIEF FINANCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Unit F1, F2 | 7,800 | $0.00 | $0.00 |
| Grant/Award | Share Option F3 | 31,150 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F4, F2 | 3,069 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F5 | 1,591 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F6 | 1,750 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F7 | 2,694 | $0.00 | $0.00 |
| Exercise | Class A Ordinary Share F1 | 2,694 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 1,750 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 1,591 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 3,069 | -- | -- |
| Exercise Price or Tax Liability | Class A Ordinary Share | 4,404 | $79.28 | $349K |
Holdings After Transaction:
Restricted Share Unit — 21,938 contracts (Direct);
Share Option — 31,150 contracts (Direct);
Class A Ordinary Share — 20,854 shares (Direct)
Footnotes (7)
- F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
- F3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
- F4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
- F5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
- F6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
- F7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Key Figures
New RSU grant: 7,800 units
New share option grant: 31,150 shares
Option exercise price: $79.28 per share
+3 more
6 metrics
New RSU grant
7,800 units
Restricted Share Units granted to the CFO on September 1, 2026
New share option grant
31,150 shares
Share option for Class A Ordinary Shares granted on September 1, 2026
Option exercise price
$79.28 per share
Exercise price of the 31,150-share option granted to the CFO
Option expiration date
August 31, 2036
Stated expiration date of the CFO’s new share option
Derivative exercises
9,104 units
Restricted Share Units exercised or converted on September 1, 2026
Shares for exercise price or tax liability
4,404 shares
Class A Ordinary Shares delivered or withheld at $79.28 per share
Key Terms
Restricted Share Unit, Class A Ordinary Share, vests over a four-year period, exercise price
4 terms
vests over a four-year period financial
"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026."
exercise price financial
"Payment of exercise price or tax liability by delivering or withholding securities"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What equity awards did KNSA grant to its CFO on September 1, 2026?
On September 1, 2026, Kiniksa’s CFO Mark Ragosa received 7,800 Restricted Share Units and a share option for 31,150 Class A Ordinary Shares with an exercise price of $79.28 per share, both subject to multi‑year vesting schedules.
What RSU vesting and conversions did KNSA report for its CFO?
Kiniksa reported that earlier Restricted Share Units granted in 2022, 2023, 2024 and 2025 vested on September 1, 2026 and were converted into Class A Ordinary Shares, consistent with four‑year vesting schedules with 25% vesting on each yearly anniversary.
Were KNSA insider transactions made under a Rule 10b5-1 plan?
No. The filing indicates that the transactions reported for Kiniksa’s CFO on September 1, 2026 were not made pursuant to a Rule 10b5‑1 trading plan.
How do the new RSU awards for KNSA’s CFO vest over time?
Each new Restricted Share Unit for Kiniksa’s CFO represents a right to one Class A Ordinary Share and vests over four years, with 25% vesting on each yearly anniversary of the September 1, 2026 grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
